Correlation between ADAMTS13 activity and neurological impairment in acute thrombotic microangiopathy patients

被引:7
作者
de Marinis, Giulia Berti [1 ]
Novello, Stefano [2 ]
Ferrari, Silvia [2 ]
Barzon, Isabella [2 ]
Cortella, Irene [2 ]
Businaro, Maria Antonietta [2 ]
Fabris, Fabrizio [2 ]
Lombardi, Anna Maria [2 ]
机构
[1] Univ Hosp Padova, Emergency Dept, Via Giustiniani 2, I-35128 Padua, Italy
[2] Univ Padua, Dept Med, Internal Med, Padua, Italy
关键词
TTP; ADAMTS13; activity; Epilepsy; Thrombotic microangiopathy; FACTOR-CLEAVING PROTEASE; THROMBOCYTOPENIC PURPURA; ANTI-ADAMTS13; ANTIBODIES; DIAGNOSIS; OUTCOMES;
D O I
10.1007/s11239-016-1395-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Differential diagnosis between thrombotic thrombocytopenic purpura (TTP) and other thrombotic microangiopathies (TMA) is usually difficult because of frequently overlapping clinical presentations. Severely depressed ADAMTS13 activity (< 10 %) seems distinctive for TTP because of its pathogenetic role. However a long debate exists in the literature about its sensibility and specificity. Our aim was to search for clinical differences between TMA patients referred to our laboratory, comparing them for protease activity < 10 versus aeyen10 %. ADAMTS13 activity aeyen10 % patients (n = 73) showed a higher prevalence of drug- (p = 0.005) and cancer-associated (p < 0.001) TMA. Mean platelet count and renal dysfunction prevalence was lower (p < 0.001), while neurological impairment was more frequent (p = 0.001) in the < 10 % ADAMTS13 activity group (n = 109), confirming previous literature findings. When taken neurological manifestations singularly, epilepsy (p = 0.04), focal motor deficit (p < 0.001) and cranial nerve palsy (p = 0.007) were more frequent in the < 10 % activity group. In our case series, a < 10 % ADAMTS13 activity depicts a group of patients with clinical features similar to TTP patients. Focal motor impairment or epileptic manifestations could further address toward a TTP diagnosis. Studies about treatment efficacy and follow-up are advised to determine whether laboratory findings can guide therapeutic decisions.
引用
收藏
页码:586 / 592
页数:7
相关论文
共 23 条
  • [21] Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
    Tsai, HM
    Lian, ECY
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (22) : 1585 - 1594
  • [22] ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome:: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients
    Vesely, SK
    George, JN
    Lämmle, B
    Studt, JD
    Alberio, L
    El-Harake, MA
    Raskob, GE
    [J]. BLOOD, 2003, 102 (01) : 60 - 68
  • [23] Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity
    Zafrani, L.
    Mariotte, E.
    Darmon, M.
    Canet, E.
    Merceron, S.
    Boutboul, D.
    Veyradier, A.
    Galicier, L.
    Azoulay, E.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (03) : 380 - 389